Orelabrutinib not checked

Beijing InnoCare Pharma Tech Co., Ltd. · ICP-022 · ICP-022+ R-CHOP

FollowEvery change as it happens, and a Monday email
Stage
in China
Next date
Phase 3 trial completes
Trials
8 active
26 in total · 3 in the EU
Targets
 

What this is

How it works
Blocks BTK, an enzyme B cells (a type of immune cell) need to grow and work. Used against some blood cancers and immune diseases.-brutinib: Bruton's tyrosine kinase inhibitors WHO name stem
How it’s given
“Participants receive orelabrutinib 150 mg oral once daily continuous dosing; each cycle is 28 days.”In the company’s words, NCT07896590 on ClinicalTrials.gov
Tested for
Relapsed/Refractory Marginal Zone Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (MZL), Multiple Sclerosis (MS) Primary Progressive, Secondary Progressive Multiple Sclerosis, Mantle Cell Lymphoma, Relapsed or Refractory Mantle Cell Lymphoma (MCL), Hematologic Malignancies, Part 1:r/r B-cell Malignancies and 1 more
Main trialPhase 3
“Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma”In the company’s words, NCT06082102 on ClinicalTrials.gov
Other names
ICP-022 · ICP-022+ R-CHOP

Other drugs for Relapsed/Refractory Marginal Zone Lymphoma

All 34 drugs for Relapsed/Refractory Marginal Zone Lymphoma

Coming up7

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials26

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 31 Aug 2028 Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Phase 3Not yet recruiting Oct 2028 Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
Phase 3Recruiting Jun 2030 A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Phase 3Recruiting Jun 2030 A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Phase 3Recruiting 25 Jun 2031 A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Phase 3Not yet recruiting Oct 2032 A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
Phase 2/3Recruiting 25 Nov 2030 ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Phase 1/2Active, not recruiting 30 Jun 2026 A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
Phase 3Unknown 30 Jul 2024 A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma
Phase 3Unknown 30 Dec 2024 ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
Phase 3Unknown 31 Dec 2025 Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia
Phase 2Completed 5 Nov 2021 A Study of ICP-022 in Patients With R/R DLBCL
Phase 2Completed 27 Dec 2023 A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
Phase 2Unknown 30 Dec 2023 A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia
Phase 2Unknown 31 Dec 2023 A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
Phase 2Completed 9 Jan 2024 A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
Phase 2Completed 10 Dec 2024 Evaluating Different Doses of Orelabrutinib in MCL
Phase 2Unknown 25 Aug 2025 Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
Phase 2Unknown 25 Feb 2026 A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
Phase 1/2Completed 10 Apr 2020 A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)
Phase 1/2Completed 28 Apr 2022 A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
Phase 1/2Unknown 31 Dec 2022 A Study to Evaluate ICP-022 in Patients With CLL/ SLL
Phase 1/2Unknown 30 Dec 2025 A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
Phase 1Completed 4 Jan 2022 DDI Study of Orelabrutinib
Phase 1Unknown 30 Jun 2023 Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
Phase 1Unknown 30 Dec 2023 Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Orelabrutinib

Following is part of Solo: you see every change to Orelabrutinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in